Systemic sclerosis & Raynaud's

Increased serum soluble interleukin-2 receptor concentrations are linked to high-sensitivity troponin T and disease progression in systemic sclerosis

Clin Exp RheumatolPublished Longitudinal cross-sectional observational study

Authors' conclusion

sIL-2R concentrations reflect disease severity, particularly cardiac damage, and early disease progression, and suggest a potential role for disease and therapy monitoring.

Study context

Population
Patients with systemic sclerosis (SSc), clinical data at baseline and up to 48 months after
Participants
315 patients
Exposure
dcSSc vs lcSSc; sIL-2R ≥900 U/ml vs lower
  • dcSScn = 139
  • lcSScn = 176reference
Outcome
Serum sIL-2R concentrations as biomarker in SSc and their association with hs-CRP, b2M and hs-TnT
Methodological detailslogistic regression, Kaplan-Meier method, Mantel-Cox proportional hazard models
  • Logistic regression
  • Kaplan-Meier method
  • Mantel-Cox proportional hazard models

Main finding

As reported in the abstract

Serum sIL-2R concentrations
sIL-2R correlation with b2M
r=0.6161, p<0.001
sIL-2R correlation with hs-CRP
r=0.4091, p<0.001
sIL-2R correlation with hs-TnT
r=0.4548, p<0.001
Increase in sIL-2R associated with cardiac involvement
p=0.014
Increase in sIL-2R associated with pulmonary involvement
p=0.007
Increase in sIL-2R associated with skin involvement
p<0.001

Observational data: associations, not effects.

Further findings

OutcomeValuesHRP value
sIL-2R discrimination of normal vs pathological hs-TnTsIL-2R AUC 0.87 · 95% CI 0.77-0.97 · P p<0.001 · sensitivity 80.0% · specificity 80.1%
Early disease progression, sIL-2R ≥900 U/mlLog-rank test and Mantel-Cox proportional hazard models2.21P = 0.001

sIL-2R in patients with clinical improvement

sIL-2R concentration decreased
P = 0.004

Original publication

Increased serum soluble interleukin-2 receptor concentrations are linked to high-sensitivity troponin T and disease progression in systemic sclerosis. Clin Exp Rheumatol. Published 24 October 2024. doi:10.55563/clinexprheumatol/re755k

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.